CA2341974A1 - Gonadotropin releasing hormone antagonist - Google Patents
Gonadotropin releasing hormone antagonist Download PDFInfo
- Publication number
- CA2341974A1 CA2341974A1 CA002341974A CA2341974A CA2341974A1 CA 2341974 A1 CA2341974 A1 CA 2341974A1 CA 002341974 A CA002341974 A CA 002341974A CA 2341974 A CA2341974 A CA 2341974A CA 2341974 A1 CA2341974 A1 CA 2341974A1
- Authority
- CA
- Canada
- Prior art keywords
- antagonist
- gnrh
- gnrh antagonist
- amount
- ganirelix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a method to prevent a premature LH surge. T he method employs the administration of the gonadotropin releasing hormone antagonist ganirelix in an amount dependent on the body weight of the patien t. The method can be used in combination with administration of exogenous FSH i n the treatment of women undergoing controlled ovarian superovulation.
Description
Gonadotropin releasing hormone antagonist The present invention relates to the use of GnRH antagonists in controlled s ovarian hyperstimulation (COH) as well as to a method to prevent premature LH surge. It also relates to a cartridge comprising said antagonist and a kit comprising said cartridge and FSH.
The glycoprotein hormones Luteinizing Hormone (LH) and Follicle ~o Stimulating Hormone (FSH) are released from the pituitary gland under control of Gonadotropin Releasing Hormone (GnRH). They act on the ovary to stimulate steroid synthesis and secretion and thus play a central role in the reproductive cycle.
In the normal cycle, there is a mid-cycle surge in LH concentration which is ~5 followed by ovulation. The LH surge is a consequence of the raise in estrogen levels brought about by the endogenous secretion of LH and FSH. The estrogen is part of a positive feedback mechanism resulting in the elevated LH
level.
2o GnRH analogues are useful for a variety of disorders in which immediate reversible suppression of the pituitary-gonadal axis is desired. This can in principle be achieved with GnRH agonists as well as with GnRH antagonists.
In comparison to GnRH agonists, GnRH antagonists have the advantage of not inducing an initial release of gonadotropins (flare-up) and steroids before 25 suppression.
Currently, GnRH agonists are clinically applied for the prevention of endogenous LH-surges during controlled ovarian hyperstimulation for Assisted Reproduction Techniques (ART). Specific disadvantages of GnRH agonists are the initial flare-up and the rather long period until pituitary suppression 3o becomes effective. Usually, patients undergoing COH start only treatment with (recombinant) FSH after 2 to 3 weeks pretreatment with GnRH agonists.
Women treated for this purpose without GnRH analogues, all show attenuated LH rises irrespective of the treatment schedule used. Usually these rises occur prematurely due to a positive feedback of rising estradiol (E2) produced by a cohort of relative small follicles. The exposure of non-mature follicles to high levels of LH leads to premature iuteinisation of granulosa cells and hence to increased production of progesterone and decreased synthesis of E2. These changes lead to disrupted maturation and decreased fertilization J and implantation rates. Success rates of COH cycles in which premature LH
rises are detected, are reported to be low and often these cycles are canceled because the number and/or size of follicles is still too small.
GnRH antagonists by GnRH receptor competition provide an immediate ~o inhibition of gonadotropin secretion, especially of LH. Thus, during COH by FSH, GnRH antagonist treatment is only required during the few days when there is an increased risk for a premature LH surge. It has been found that the GnRH antagonist dosage range is critical: too low a GnRH antagonist dosage leading to Armature LH rises, while too high a GnRH antagonist dosage ~5 hampered follicular maturation. For the antagonist ganirelix for example a fixed amount being at least 0.125 mg but less than 1 mg and preferably about 0.25 mg was suggested (W098/58657).
Surprisingly, however, it has now been found that there is no relationship between the implantation rate and level of LH (AUC), whereas there does exist Zo a relationship between the GnRH antagonist levels (AUC) and the implantation rate. It has now been found that antagonist is to be administered in an amount depending on the body weight (BW).
The invention therefore relates to a pharmaceutical preparation comprising GnRH antagonist, while applying a dosage adjusted for body weight sufficient z5 to prevent a premature LH surge and ensuring successful treatment outcome.
Such preparation is useful in the treatment of women undergoing COH.
A preferred antagonist according to the present invention is ganirelix which has the following chemical name:
N-Acetyl-3-(2-naphtyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-3o alanyl-L-seryl-L-N9,N'°-diethyl-D-homoarginyl-L-leucin-N9,N'°-diethyl-L-homoarginyl-L-propyl-D-alanylamide acetate. The abbreviated structure is [N-Ac-D-Na(2)' , D-pCIPhe2,D-Pal(3)3, D-hArg(Et2)6, L-hArg(Et2)8, D-Ala' °-GnRH.
The GnRH antagonist ganirelix is disclosed in US patent No. 4,801,577 for nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists.
This patent, which is fully incorporated herein by reference, describes the method for the preparation of these compounds. It is indicated that the s compounds described therein can be used for the prevention of ovarian hyperstimulation. For human therapy a daily range is suggested for administration of the active ingredient between 0.001 and 5 mglkg body weight, preferably between 0.01 and 1 mglkg.
It has now been found that the optimal relationship between body weight ~o and GnRH antagonist dosage can be defined (in micrograms) by the Formula:
(5.5*BW - 166) ~ 7% (Formula I) wherein BW represents the body weight of the patient in kg.
The preparation is administered together with FSH during the days of ovarian stimulation when a premature LH rise may easily occur e.g. from day 5 ~s of FSH administration onwards. The preparation in its proposed dosage range has the advantage of providing an immediate effect that prevents an LH surge and at the same time maximizes the chances of establishing pregnancy.
Administration is usually stopped when sufficient follicles have matured and exogenous hCG/LH is given for induction of ovulation. The amount of hCG/LH
2o usually amounts 5000-10000 IU. Alternatively, induction of ovulation can be performed by administration of a GnRH agonist. The agonist instead of hCG/LH is usually given on the same day in an amount sufficient to trigger ovulation. A suitable range is 10-1000 fig. Suitable agonists are e.g.
buserelin, triptorelin and luprorelin.
2s The exact regimen for administration might depend on the individual response and is finally to be decided by the clinician who treats the subject.
For this reason the duration of initial ovarian stimulation with FSH alone as well as the duration of combined treatment with FSH/GnRH antagonist treatment may vary. FSH treatment usually starts at menses day 1, 2 or 3. Ovarian so stimulation with FSH alone may be continued up to 5 days in an amount of e.g.
150-225 IU. FSH is administered preferably as a recombinant protein.
Treatment with GnRH antagonist may be started at the first day of FSH, but preferably such treatment starts at FSH treatment day 4 or 5. The GnRH
antagonist is administered in the previously determined amount according to 35 the invention in combination with FSH in amounts between 50 - 600 IU, preferably between 100 - 300 IU. GnRH antagonist treatment may last 2 - 14 WO 01/002Z? PCT1EP00/05643 _ q _ days i.e. up to the moment whereupon the patient is treated with exogenous LHIhCG or a GnRH or GnRH agonist for ovulation induction.
According to another aspect of the invention ganirelix in an amount according to Formula I is used for the manufacture of a medicament to prevent s a premature LH surge in women undergoing controlled ovarian hyperstimulation.
The pharmaceutical preparations for use according to the invention can be prepared in accordance with standard techniques such as for example are ~o described in the standard reference, Gennaro et al. (Ed.), Remmington's Pharmaceutical Sciences, (18t" ed. Mack Publishing Company, 1990, e.g. Part 8: Pharmaceutical Preparations And Their Manufacture). For the purpose of making the pharmaceutical preparations according to the invention, the active substance is mixed with or dissolved in a pharmaceutical acceptable carrier.
~s Any conventional pharmaceutical carrier that does not interfere with performance of the active ingredient can be used in the preparations according to the present invention. Formulations may contain as common excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated 2o naphtalenes and the like.
The pharmaceutical preparation of the antagonist may be administered parenterally. Preferably it is administered subcutaneously, particularly in the form of liquid solutions or suspensions. A typical formulation is a solution containing, in addition to the active substance in an amount as indicated 2s above, glacial acetic acid, mannitol, and water adjusted to pH 5 with sodium hydroxide and / or hydrochloric acid. Optionally preservations such as e.g.
methyl- and propylparaben or benzylalcohol can be added. The solutions can be packaged e.g. in glass vials, cartridges or in syringes.
3o In a further aspect of the invention there is provided a cartridge containing a sterile liquid formulation of ganirelix. As used herein a cartridge means a closed container, such as an ampoule, a vial, a bottle or a bag comprising an amount of GnRH antagonist so as to administer accurately and preferably repeatedly to a patient a dosage of GnRH antagonist according to Formula I.
Thus, a cartridge may contain an amount of the liquid antagonist formulation corresponding to one or more therapeutic dosages of the antagonist. Preferably these dosages are to be applied in a single regimen.
Preferably the cartridges contain an amount of GnRH antagonist sufficient for s 5 administrations. The cartridges are preferably used in combination with a device making it possible to deliver adjustable dosages needed in the regimen.
In another aspect of the invention there is provided a device for administration comprising a cartridge containing a sterile liquid formulation according to the invention. A preferred device for administration is a pen-type ~o injector, which comprise means for easy adjustment of the amount of a formulation that is to be injected. Such pen type injectors are known per se, such as for instance the well known B-D Pen (a trademark of Becton Dickinson and Company), an insulin-injection system.
Adjustable cartridges according to the invention have the advantage of ~5 accurate self-administration thereby increasing the convenience for the patients.
In yet another aspect of the invention there is provided a kit for use in controlled ovarian hyperstimulation in female patients. Such a kit comprises a zo GnRH antagonist in a dosage form and quantity so as to accurately administer to a patient in an amount according to Formula I, in a frequency effective to prevent a premature LH surge. In addition the kit comprises FSH in a dosage form and quantity suitable for administering in an amount and frequency effective to stimulate growth of follicles. Optionally the kit may comprise also z5 hCGILH or GnRH agonists in a dosage form and quantity suitable for administering in an amount and frequency effective to induce ovulation. The GnRH antagonist preferably is packaged in a cartridge. This cartridge preferably is to be used in combination with a device for administration such as a pen type injector allowing an adjustable and accurate administration of so GnRH antagonist. Thus, the kit might also comprise a pen type injector system.
The invention is further explained by reference to the following Examples.
Legends to the Figures Figure 1: LH levels were measured at the start (just before the first injection of ganirelix) and end of ganirelix treatment. The graph shows the s pregnancies in relation to the various levels. LH levels are indicated in IU/L.
Figure 2: Area under the curve of ganirelix versus body weight of subjects in three pharmacokinetic studies. Circles mean protocol A; triangles mean protocol B and squares mean protocol C.
Figure 3: Chance of pregnancy versus body weight; results from Phase III
efficacy study. Dots in the top of the graph correspond to pregnant subjects (100%), while for subjects not pregnant (0%) these dots are displayed at the bottom of the graph. The spline function (chance of pregnancy vs body weight) is the resulting curve of these observations.
Examples Example 1 LH serum levels versus pregnancy Recombinant FSH (recFSH) treatment was started on day 2 or 3 of the s menstrual cycle by a once daily SC injection. Just prior to the first injection of recFSH an hCG test was performed to exclude pregnancy, a blood sample for hormone analysis was taken and an ultrasonography (USS) was performed.
During recFSH treatment day 1 through 5, the daily dose of recFSH was fixed to 150 international units (IU). On day 6 of recFSH treatment ganirelix ~o treatment was started by daily SC administration until and including the day before the day of hCG.
During ganirelix treatment, the dose of recFSH was adjusted depending on the individual ovarian response as assessed by USS. From the first day of ganirelix i.e. from recFSH treatment day 6 onwards up to and including the day ~s of hCG, a blood sample for hormone analysis was taken prior to drug administration. And an USS was performed, at least every two days.
LH levels were assessed by a standard LH specific assay at the Central Laboratory of the Analytisch Biochemisch Laboratorium (Assen, The Netherlands). From the data on LH levels, a plot was constructed in order to zo investigate the possible role of LH on pregnancy.
LH levels were measured at the start (just before the first injection of ganirelix) and end of ganirelix treatment. Figure 1 shows the pregnancies in relation to the various levels.
Clearly, from this graph, no relationship between LH serum levels and z5 pregnancy outcome was found.
Example 2 Body Weight versus pregnancy For the body weight parameter the treated groups of example 1 were divided 3o into categories of a 10 kg range and the pregnancy rates found for these separate categories were investigated. The results are indicated in Table 1 - a -Weight (kg) Pregnancy rate <50 9%
50-60 16%
60-70 22%
70-80 22%
>=80 22%
Table 1: Relationship between pregnancy and body weight From this table a relationship between the parameter body weight and clinical outcome (i.e. pregnancy) was observed.
Example 3 Body weight vs AUC
Several pharmacokinetic studies were carried out with ganirelix. Protocol A: an open-label two-way crossover study to assess the absolute bioavailablity of 0.25 mg ganirelix after single injection. Protocol B: an open-label randomized, multiple dose parallel-design study to assess the dose-proportionality and the pharmacokinetic properties of ganirelix (0.125 , 0.25 and 0.5 mg) after repeated subcutaneous administration. Protocol C: an open, randomized, two-way crossover study to establish the local tolerance and bioavailability of ganirelix after multiple subcutaneous administration (2 mg).
In all these trials A, B and C, blood samples were taken at regular intervals and the amount of ganirelix present in the blood was determined. Plots were prepared showing the amount of ganirelix as a function of time. This allowed zo the determination of the AUC. Next, the AUC was related to the body weight of the subjects. Results are indicated in Figure 2.
A pooled analysis of the three pharmacokinetic studies has demonstrated that the clearance of ganirelix is positively related to body weight. This is expressed in a lower area under the curve (AUC) for subjects with a higher 25 body weight (Figure 2). Thus at the same dose level, individuals with a relatively high body weight will be exposed to lower levels of ganirefix, and individuals with a low body weight to relatively high levels.
_ g _ As body weight is related to ganirelix levels it can be expected that body weight influences the clinical outcome.
This hypothesis is supported by the results of a large Phase III efficacy study. At lower body weights a significant decrease in pregnancy rate was s observed (see example 1 and Figure 3). These subjects have been exposed to relatively higher levels of ganirelix. The pregnancy rate therefore could be optimized in these individuals by adjustment of the dose, according to their body weights.
Example 4 Dose finding Pharmaco-statistical models have been set up to describe the influence of body weight on the effectiveness of ganirelix for both the prevention of LH-rises and pregnancy outcome. Spline functions have been applied to give the best and assumptionless mathematical description of the available data. Using these models optimal doses with respect to the prevention of LH-rises and pregnancy have been determined for different body weights.
Weight (kg) Optimal dose ( Ng) <50 <128 >=g0 >264 Table 2: Relationship between body weight and optimal dose Results are indicated in Table 2. Linear regression shows that these dosages can be given by the formula: (5.5*BW -166) ~ 7% wherein BW is the body weight in kg.
The glycoprotein hormones Luteinizing Hormone (LH) and Follicle ~o Stimulating Hormone (FSH) are released from the pituitary gland under control of Gonadotropin Releasing Hormone (GnRH). They act on the ovary to stimulate steroid synthesis and secretion and thus play a central role in the reproductive cycle.
In the normal cycle, there is a mid-cycle surge in LH concentration which is ~5 followed by ovulation. The LH surge is a consequence of the raise in estrogen levels brought about by the endogenous secretion of LH and FSH. The estrogen is part of a positive feedback mechanism resulting in the elevated LH
level.
2o GnRH analogues are useful for a variety of disorders in which immediate reversible suppression of the pituitary-gonadal axis is desired. This can in principle be achieved with GnRH agonists as well as with GnRH antagonists.
In comparison to GnRH agonists, GnRH antagonists have the advantage of not inducing an initial release of gonadotropins (flare-up) and steroids before 25 suppression.
Currently, GnRH agonists are clinically applied for the prevention of endogenous LH-surges during controlled ovarian hyperstimulation for Assisted Reproduction Techniques (ART). Specific disadvantages of GnRH agonists are the initial flare-up and the rather long period until pituitary suppression 3o becomes effective. Usually, patients undergoing COH start only treatment with (recombinant) FSH after 2 to 3 weeks pretreatment with GnRH agonists.
Women treated for this purpose without GnRH analogues, all show attenuated LH rises irrespective of the treatment schedule used. Usually these rises occur prematurely due to a positive feedback of rising estradiol (E2) produced by a cohort of relative small follicles. The exposure of non-mature follicles to high levels of LH leads to premature iuteinisation of granulosa cells and hence to increased production of progesterone and decreased synthesis of E2. These changes lead to disrupted maturation and decreased fertilization J and implantation rates. Success rates of COH cycles in which premature LH
rises are detected, are reported to be low and often these cycles are canceled because the number and/or size of follicles is still too small.
GnRH antagonists by GnRH receptor competition provide an immediate ~o inhibition of gonadotropin secretion, especially of LH. Thus, during COH by FSH, GnRH antagonist treatment is only required during the few days when there is an increased risk for a premature LH surge. It has been found that the GnRH antagonist dosage range is critical: too low a GnRH antagonist dosage leading to Armature LH rises, while too high a GnRH antagonist dosage ~5 hampered follicular maturation. For the antagonist ganirelix for example a fixed amount being at least 0.125 mg but less than 1 mg and preferably about 0.25 mg was suggested (W098/58657).
Surprisingly, however, it has now been found that there is no relationship between the implantation rate and level of LH (AUC), whereas there does exist Zo a relationship between the GnRH antagonist levels (AUC) and the implantation rate. It has now been found that antagonist is to be administered in an amount depending on the body weight (BW).
The invention therefore relates to a pharmaceutical preparation comprising GnRH antagonist, while applying a dosage adjusted for body weight sufficient z5 to prevent a premature LH surge and ensuring successful treatment outcome.
Such preparation is useful in the treatment of women undergoing COH.
A preferred antagonist according to the present invention is ganirelix which has the following chemical name:
N-Acetyl-3-(2-naphtyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-3o alanyl-L-seryl-L-N9,N'°-diethyl-D-homoarginyl-L-leucin-N9,N'°-diethyl-L-homoarginyl-L-propyl-D-alanylamide acetate. The abbreviated structure is [N-Ac-D-Na(2)' , D-pCIPhe2,D-Pal(3)3, D-hArg(Et2)6, L-hArg(Et2)8, D-Ala' °-GnRH.
The GnRH antagonist ganirelix is disclosed in US patent No. 4,801,577 for nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists.
This patent, which is fully incorporated herein by reference, describes the method for the preparation of these compounds. It is indicated that the s compounds described therein can be used for the prevention of ovarian hyperstimulation. For human therapy a daily range is suggested for administration of the active ingredient between 0.001 and 5 mglkg body weight, preferably between 0.01 and 1 mglkg.
It has now been found that the optimal relationship between body weight ~o and GnRH antagonist dosage can be defined (in micrograms) by the Formula:
(5.5*BW - 166) ~ 7% (Formula I) wherein BW represents the body weight of the patient in kg.
The preparation is administered together with FSH during the days of ovarian stimulation when a premature LH rise may easily occur e.g. from day 5 ~s of FSH administration onwards. The preparation in its proposed dosage range has the advantage of providing an immediate effect that prevents an LH surge and at the same time maximizes the chances of establishing pregnancy.
Administration is usually stopped when sufficient follicles have matured and exogenous hCG/LH is given for induction of ovulation. The amount of hCG/LH
2o usually amounts 5000-10000 IU. Alternatively, induction of ovulation can be performed by administration of a GnRH agonist. The agonist instead of hCG/LH is usually given on the same day in an amount sufficient to trigger ovulation. A suitable range is 10-1000 fig. Suitable agonists are e.g.
buserelin, triptorelin and luprorelin.
2s The exact regimen for administration might depend on the individual response and is finally to be decided by the clinician who treats the subject.
For this reason the duration of initial ovarian stimulation with FSH alone as well as the duration of combined treatment with FSH/GnRH antagonist treatment may vary. FSH treatment usually starts at menses day 1, 2 or 3. Ovarian so stimulation with FSH alone may be continued up to 5 days in an amount of e.g.
150-225 IU. FSH is administered preferably as a recombinant protein.
Treatment with GnRH antagonist may be started at the first day of FSH, but preferably such treatment starts at FSH treatment day 4 or 5. The GnRH
antagonist is administered in the previously determined amount according to 35 the invention in combination with FSH in amounts between 50 - 600 IU, preferably between 100 - 300 IU. GnRH antagonist treatment may last 2 - 14 WO 01/002Z? PCT1EP00/05643 _ q _ days i.e. up to the moment whereupon the patient is treated with exogenous LHIhCG or a GnRH or GnRH agonist for ovulation induction.
According to another aspect of the invention ganirelix in an amount according to Formula I is used for the manufacture of a medicament to prevent s a premature LH surge in women undergoing controlled ovarian hyperstimulation.
The pharmaceutical preparations for use according to the invention can be prepared in accordance with standard techniques such as for example are ~o described in the standard reference, Gennaro et al. (Ed.), Remmington's Pharmaceutical Sciences, (18t" ed. Mack Publishing Company, 1990, e.g. Part 8: Pharmaceutical Preparations And Their Manufacture). For the purpose of making the pharmaceutical preparations according to the invention, the active substance is mixed with or dissolved in a pharmaceutical acceptable carrier.
~s Any conventional pharmaceutical carrier that does not interfere with performance of the active ingredient can be used in the preparations according to the present invention. Formulations may contain as common excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated 2o naphtalenes and the like.
The pharmaceutical preparation of the antagonist may be administered parenterally. Preferably it is administered subcutaneously, particularly in the form of liquid solutions or suspensions. A typical formulation is a solution containing, in addition to the active substance in an amount as indicated 2s above, glacial acetic acid, mannitol, and water adjusted to pH 5 with sodium hydroxide and / or hydrochloric acid. Optionally preservations such as e.g.
methyl- and propylparaben or benzylalcohol can be added. The solutions can be packaged e.g. in glass vials, cartridges or in syringes.
3o In a further aspect of the invention there is provided a cartridge containing a sterile liquid formulation of ganirelix. As used herein a cartridge means a closed container, such as an ampoule, a vial, a bottle or a bag comprising an amount of GnRH antagonist so as to administer accurately and preferably repeatedly to a patient a dosage of GnRH antagonist according to Formula I.
Thus, a cartridge may contain an amount of the liquid antagonist formulation corresponding to one or more therapeutic dosages of the antagonist. Preferably these dosages are to be applied in a single regimen.
Preferably the cartridges contain an amount of GnRH antagonist sufficient for s 5 administrations. The cartridges are preferably used in combination with a device making it possible to deliver adjustable dosages needed in the regimen.
In another aspect of the invention there is provided a device for administration comprising a cartridge containing a sterile liquid formulation according to the invention. A preferred device for administration is a pen-type ~o injector, which comprise means for easy adjustment of the amount of a formulation that is to be injected. Such pen type injectors are known per se, such as for instance the well known B-D Pen (a trademark of Becton Dickinson and Company), an insulin-injection system.
Adjustable cartridges according to the invention have the advantage of ~5 accurate self-administration thereby increasing the convenience for the patients.
In yet another aspect of the invention there is provided a kit for use in controlled ovarian hyperstimulation in female patients. Such a kit comprises a zo GnRH antagonist in a dosage form and quantity so as to accurately administer to a patient in an amount according to Formula I, in a frequency effective to prevent a premature LH surge. In addition the kit comprises FSH in a dosage form and quantity suitable for administering in an amount and frequency effective to stimulate growth of follicles. Optionally the kit may comprise also z5 hCGILH or GnRH agonists in a dosage form and quantity suitable for administering in an amount and frequency effective to induce ovulation. The GnRH antagonist preferably is packaged in a cartridge. This cartridge preferably is to be used in combination with a device for administration such as a pen type injector allowing an adjustable and accurate administration of so GnRH antagonist. Thus, the kit might also comprise a pen type injector system.
The invention is further explained by reference to the following Examples.
Legends to the Figures Figure 1: LH levels were measured at the start (just before the first injection of ganirelix) and end of ganirelix treatment. The graph shows the s pregnancies in relation to the various levels. LH levels are indicated in IU/L.
Figure 2: Area under the curve of ganirelix versus body weight of subjects in three pharmacokinetic studies. Circles mean protocol A; triangles mean protocol B and squares mean protocol C.
Figure 3: Chance of pregnancy versus body weight; results from Phase III
efficacy study. Dots in the top of the graph correspond to pregnant subjects (100%), while for subjects not pregnant (0%) these dots are displayed at the bottom of the graph. The spline function (chance of pregnancy vs body weight) is the resulting curve of these observations.
Examples Example 1 LH serum levels versus pregnancy Recombinant FSH (recFSH) treatment was started on day 2 or 3 of the s menstrual cycle by a once daily SC injection. Just prior to the first injection of recFSH an hCG test was performed to exclude pregnancy, a blood sample for hormone analysis was taken and an ultrasonography (USS) was performed.
During recFSH treatment day 1 through 5, the daily dose of recFSH was fixed to 150 international units (IU). On day 6 of recFSH treatment ganirelix ~o treatment was started by daily SC administration until and including the day before the day of hCG.
During ganirelix treatment, the dose of recFSH was adjusted depending on the individual ovarian response as assessed by USS. From the first day of ganirelix i.e. from recFSH treatment day 6 onwards up to and including the day ~s of hCG, a blood sample for hormone analysis was taken prior to drug administration. And an USS was performed, at least every two days.
LH levels were assessed by a standard LH specific assay at the Central Laboratory of the Analytisch Biochemisch Laboratorium (Assen, The Netherlands). From the data on LH levels, a plot was constructed in order to zo investigate the possible role of LH on pregnancy.
LH levels were measured at the start (just before the first injection of ganirelix) and end of ganirelix treatment. Figure 1 shows the pregnancies in relation to the various levels.
Clearly, from this graph, no relationship between LH serum levels and z5 pregnancy outcome was found.
Example 2 Body Weight versus pregnancy For the body weight parameter the treated groups of example 1 were divided 3o into categories of a 10 kg range and the pregnancy rates found for these separate categories were investigated. The results are indicated in Table 1 - a -Weight (kg) Pregnancy rate <50 9%
50-60 16%
60-70 22%
70-80 22%
>=80 22%
Table 1: Relationship between pregnancy and body weight From this table a relationship between the parameter body weight and clinical outcome (i.e. pregnancy) was observed.
Example 3 Body weight vs AUC
Several pharmacokinetic studies were carried out with ganirelix. Protocol A: an open-label two-way crossover study to assess the absolute bioavailablity of 0.25 mg ganirelix after single injection. Protocol B: an open-label randomized, multiple dose parallel-design study to assess the dose-proportionality and the pharmacokinetic properties of ganirelix (0.125 , 0.25 and 0.5 mg) after repeated subcutaneous administration. Protocol C: an open, randomized, two-way crossover study to establish the local tolerance and bioavailability of ganirelix after multiple subcutaneous administration (2 mg).
In all these trials A, B and C, blood samples were taken at regular intervals and the amount of ganirelix present in the blood was determined. Plots were prepared showing the amount of ganirelix as a function of time. This allowed zo the determination of the AUC. Next, the AUC was related to the body weight of the subjects. Results are indicated in Figure 2.
A pooled analysis of the three pharmacokinetic studies has demonstrated that the clearance of ganirelix is positively related to body weight. This is expressed in a lower area under the curve (AUC) for subjects with a higher 25 body weight (Figure 2). Thus at the same dose level, individuals with a relatively high body weight will be exposed to lower levels of ganirefix, and individuals with a low body weight to relatively high levels.
_ g _ As body weight is related to ganirelix levels it can be expected that body weight influences the clinical outcome.
This hypothesis is supported by the results of a large Phase III efficacy study. At lower body weights a significant decrease in pregnancy rate was s observed (see example 1 and Figure 3). These subjects have been exposed to relatively higher levels of ganirelix. The pregnancy rate therefore could be optimized in these individuals by adjustment of the dose, according to their body weights.
Example 4 Dose finding Pharmaco-statistical models have been set up to describe the influence of body weight on the effectiveness of ganirelix for both the prevention of LH-rises and pregnancy outcome. Spline functions have been applied to give the best and assumptionless mathematical description of the available data. Using these models optimal doses with respect to the prevention of LH-rises and pregnancy have been determined for different body weights.
Weight (kg) Optimal dose ( Ng) <50 <128 >=g0 >264 Table 2: Relationship between body weight and optimal dose Results are indicated in Table 2. Linear regression shows that these dosages can be given by the formula: (5.5*BW -166) ~ 7% wherein BW is the body weight in kg.
Claims (11)
1. In the treatment of female patients undergoing controlled ovarian hyperstimulation comprising administration of exogenous FSH and a GnRH antagonist, the improvement comprising administering said antagonist in an amount depending on the body weight of the patient wherein the relationship between body weight (BW in kg) and GnRH
antagonist dosage (in micrograms) is defined by the Formula:
(5.5*BW -166) ~ 7% (Formula I).
antagonist dosage (in micrograms) is defined by the Formula:
(5.5*BW -166) ~ 7% (Formula I).
2. Treatment according to claim 1 wherein said GnRH antagonist is ganirelix.
3. A cartridge containing a sterile liquid GnRH antagonist containing formulation in an amount so as to accurately administer to a patient an amount according to Formula 1 of claim 1 or 2.
4. The cartridge of claim 3 wherein the GnRH antagonist is ganirelix.
5. A device for administration of an adjustable sterile liquid GnRH
antagonist comprising a cartridge according to claim 3 or 4.
antagonist comprising a cartridge according to claim 3 or 4.
6. Use of GnRH antagonist for the manufacture of a medicament to prevent a premature LH surge in female patients undergoing controlled ovarian hyperstimulation, the method of controlling ovarian hyperstimulation comprising administering to the patient a GnRH
antagonist in an amount depending on the body weight of the patient wherein the relationship between body weight (BW in kg) and GnRH
antagonist dosage (in micrograms) is defined by the Formula:
(5.5*BW -166) ~ 7%.
antagonist in an amount depending on the body weight of the patient wherein the relationship between body weight (BW in kg) and GnRH
antagonist dosage (in micrograms) is defined by the Formula:
(5.5*BW -166) ~ 7%.
7. Use of GnRH antagonist according to claim 6 wherein said GnRH
antagonist is ganirelix.
antagonist is ganirelix.
8. A kit for use in controlled ovarian hyperstimulation in female patients comprising a GnRH antagonist in a dosage form and quantity so as to administer accurately in an amount according to Formula I of claim 1 and a frequency effective to prevent a premature LH surge; FSH in a dosage form and quantity so as to administer in an amount and frequency effective to stimulate growth of follicles; and LH/hCG or a GnRH agonist in an dosage form and quantity so as to administer in an amount and frequency effective to induce ovulation.
9. Kit according to claim 8 wherein the antagonist is ganirelix.
10. Kit according to claims 8 or 9 wherein the antagonist is packaged in a cartridge according to claim 4.
11. Kit according to claims 9-10 comprising a device for administration of an adjustable sterile liquid amount of the antagonist.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99202027.1 | 1999-06-23 | ||
| EP99202027 | 1999-06-23 | ||
| PCT/EP2000/005643 WO2001000227A1 (en) | 1999-06-23 | 2000-06-19 | Gonadotropin releasing hormone antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2341974A1 true CA2341974A1 (en) | 2001-01-04 |
Family
ID=8240349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002341974A Abandoned CA2341974A1 (en) | 1999-06-23 | 2000-06-19 | Gonadotropin releasing hormone antagonist |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1140132A1 (en) |
| JP (1) | JP2003503358A (en) |
| AR (1) | AR024438A1 (en) |
| AU (1) | AU6263800A (en) |
| CA (1) | CA2341974A1 (en) |
| WO (1) | WO2001000227A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1684737A (en) * | 2002-06-07 | 2005-10-19 | 阿雷斯贸易股份有限公司 | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
| RS54214B2 (en) | 2010-09-29 | 2024-02-29 | Ferring Bv | Composition for use in treating infertility |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998055470A1 (en) * | 1997-06-05 | 1998-12-10 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE69831241T2 (en) * | 1997-06-20 | 2006-03-23 | Akzo Nobel N.V. | Gonadotropin releasing hormone antagonist |
-
2000
- 2000-06-19 EP EP00949193A patent/EP1140132A1/en not_active Withdrawn
- 2000-06-19 JP JP2001505935A patent/JP2003503358A/en not_active Withdrawn
- 2000-06-19 AU AU62638/00A patent/AU6263800A/en not_active Abandoned
- 2000-06-19 CA CA002341974A patent/CA2341974A1/en not_active Abandoned
- 2000-06-19 WO PCT/EP2000/005643 patent/WO2001000227A1/en not_active Application Discontinuation
- 2000-06-22 AR ARP000103116A patent/AR024438A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU6263800A (en) | 2001-01-31 |
| JP2003503358A (en) | 2003-01-28 |
| AR024438A1 (en) | 2002-10-02 |
| EP1140132A1 (en) | 2001-10-10 |
| WO2001000227A1 (en) | 2001-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZELEZNIK et al. | Ovarian responses in macaques to pulsatile infusion of follicle-stimulating hormone (FSH) and luteinizing hormone: increased sensitivity of the maturing follicle to FSH | |
| de Ziegler et al. | Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval | |
| US9107871B2 (en) | LHRH—antagonists in the treatment of fertility disorders | |
| EP0994718B1 (en) | Gonadotropin releasing hormone antagonist | |
| JP2005501918A (en) | Use of hCG in controlled superovulation stimulation | |
| Wallach et al. | Ovulation induction with pulsatile gonadotropin-releasing hormone: technical modalities and clinical perspectives | |
| Bremner et al. | Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive | |
| US20020198155A1 (en) | Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders | |
| Yen | Studies of the role of dopamine in the control of prolactin and gonadotropin secretion in humans | |
| Balasch et al. | Pituitary-ovarian suppression by the standard and half-doses of D-Trp-6-luteinizing hormone-releasing hormone depot | |
| US20030092628A1 (en) | Gonadotropin releasing hormone antagonist | |
| JP2005501919A (en) | Use of hCG and LH in controlled superovulation stimulation | |
| PL205472B1 (en) | Use of lh in controlled ovarian hyperstimulation | |
| CA2341974A1 (en) | Gonadotropin releasing hormone antagonist | |
| Lemay | Clinical appreciation of LHRH analogue formulations | |
| JP2005530818A (en) | Ovarian hyperstimulation control method and pharmaceutical kit used in the method | |
| Patrizio et al. | The use of gonadotropin-releasing hormone agonists and the efficiency of in vitro fertilization | |
| Schats et al. | The use of GnRH agonists | |
| Neves-e-Castro et al. | Use of luteinizing hormone-releasing hormone analogs in non-neoplastic gynecologic conditions | |
| CA2200541C (en) | Lhrh-antagonists in the treatment of fertility disorders | |
| Huirne et al. | The use of GnRH agonists | |
| Kuehl et al. | Incorporation of a GnRH agonist, leuprolide acetate, into regimens with exogenous gonadotropins to produce ovarian stimulation and ovulation in the nonpregnant squirrel monkey | |
| Van der Spuy et al. | Early clinical studies with LHRH antagonists in women | |
| Chaussain et al. | Treatment of precocious puberty with a long-acting preparation of D-Trp6-LHRH | |
| Bhathena | Optimising Protocols for Induction of Ovulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |